West Pharmaceutical Services, Inc. WST

370.44 (3.16) (0.85%) as of 25 Sep
Market cap
$26.3B
P/E
47.1×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

West Pharmaceutical Services, Inc. (WST) EV/Sales

As of 25 September 2026, West Pharmaceutical Services, Inc. (WST) trades at a EV/Sales of 7.8×. Over the past ten years it has ranged from 2.5× (February 2015) to 13.6× (September 2021); the current reading is higher than 67% of that period. That is above the Medical Instruments & Supplies industry median of 3.1× and above the Healthcare sector median of 3.6×.

EV/Sales, daily

Annual

Period EV/Sales Change
FY2025 6.3× (23.11%)
FY2024 8.2× (4.12%)
FY2023 8.5× 46.79%
FY2022 5.8× (52.15%)
FY2021 12.1× 26.55%
FY2020 9.6× 61.17%
FY2019 5.9× 43.77%
FY2018 4.1× (9.58%)
FY2017 4.6× 11.59%
FY2016 4.1× 33.74%

Quarterly

Period EV/Sales Change
Jun 2026 7.6× 37.55%
Mar 2026 5.5× (12.36%)
Dec 2025 6.3× 2.36%
Sep 2025 6.1× 17.24%
42 more quarters

Against its own ten years

Low 2.5× High 13.6×
Ten-year median 6.0×
Current reading's percentile 67

EV/Sales against peers

Company EV/Sales
MDLN Medline Inc. compare 1.3×
BAX Baxter International Inc. compare 1.7×
SOLV Solventum Corporation compare 2.4×
BDX Becton, Dickinson and Company compare 2.8×
COO The Cooper Companies, Inc. compare 3.1×
ALC Alcon compare 3.2×
RMD ResMed Inc. compare 5.5×
WST West Pharmaceutical Services, Inc. 7.8×
RGEN Repligen Corporation compare 13.4×
Medical Instruments & Supplies industry median 3.1×
Healthcare sector median 3.6×
Market median 2.2×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on WST